Evidence map›Paper›PMID 35455326›Full record

ArticleVaccines2022

Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern.

Christopher L D McMillan, Armira Azuar, Jovin J Y Choo, Naphak Modhiran, Alberto A Amarilla, Ariel Isaacs, Kate E Honeyman, Stacey T M Cheung, Benjamin Liang, Maria J Wurm and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity.International journal of molecular sciences · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Christopher L D McMillanSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-5316-0986
Armira AzuarSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Jovin J Y ChooSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Naphak ModhiranSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-3205-4970
Alberto A AmarillaSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-6640-3377
Ariel IsaacsSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Kate E HoneymanSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Stacey T M CheungSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Benjamin LiangSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-3304-4715
Maria J WurmExcellGene SA, CH1870 Monthey, Switzerland.
Paco PinoExcellGene SA, CH1870 Monthey, Switzerland.
Joeri KintExcellGene SA, CH1870 Monthey, Switzerland.
Germain J P FernandoSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-3260-0548
Michael J LandsbergSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Alexander A KhromykhSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0001-6206-6935
Jody Hobson-PetersSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-0139-9829
Daniel WattersonSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Paul R YoungSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-2040-5190
David A MullerSchool of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0003-4375-7890
The University of Queensland · AUTranslational Research Institute · AU

Funding

Queensland Government 2020001511
6 · The paper itself

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. The spike (S) protein found on the surface of the causative agent, the SARS-CoV-2 virus, has been the prime target for current vaccine research since antibodies directed against the S protein were found to neutralize the virus. However, as new variants emerge, mutations within the spike protein have given rise to potential immune evasion of the response generated by the current generation of SARS-CoV-2 vaccines. In this study, a modified, HexaPro S protein subunit vaccine, delivered using a needle-free high-density microarray patch (HD-MAP), was investigated for its immunogenicity and virus-neutralizing abilities. Mice given two doses of the vaccine candidate generated potent antibody responses capable of neutralizing the parental SARS-CoV-2 virus as well as the variants of concern, Alpha and Delta. These results demonstrate that this alternative vaccination strategy has the potential to mitigate the effect of emerging viral variants.

Indexed as

antibodiesCOVID-19cutaneousHD-MAPHexaProintradermalSARS-CoV-2 vaccineS proteinvirus neutralization microneedle patch

Identifiers

PMID35455326
PMCPMC9030474
OpenAlexW4223474165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.